source
- Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.
- Genmab shares jump as petosemtamab plus Keytruda halves death risk in head-neck cancer trialGenmab reported that a late-stage study of its experimental antibody petosemtamab combined with Keytruda cut the risk of death by about 50 percent compared with Keytruda alone in patients with PD‑L…